Amifostine

證據等級: L5

預測適應症: 10 個

Amifostine: From Cancer Chemo/Radioprotection to Hypertensive Disorder

One-Sentence Summary

Amifostine (WR-2721) is a cytoprotective prodrug approved for reducing normal tissue damage from cisplatin chemotherapy and head and neck radiotherapy. The TxGNN model predicts it may be relevant to Hypertensive Disorder (score: 99.995%), but a ⚠️ critical reverse warning applies: amifostine’s most common serious clinical side effect is transient hypotension, creating a direct mechanistic contradiction against its use for treating hypertension. Currently 0 clinical trials and 11 publications exist for this pairing, and none directly support amifostine as a treatment for hypertension.

Quick Overview

Item	Content
Original Indication	Cancer cytoprotection (cisplatin-induced nephrotoxicity prevention; radiation-induced xerostomia reduction)
Predicted New Indication	Hypertensive Disorder
TxGNN Prediction Score	99.995%
Evidence Level	L5 (model prediction only — no directly supporting studies)
India Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why This Prediction Was Made — and Why It Has Limitations

Amifostine is a phosphorylated aminothiol prodrug converted to its active metabolite WR-1065 by alkaline phosphatase, an enzyme more highly expressed in normal tissues than in tumors. WR-1065 is a potent free radical scavenger that selectively shields normal cells from oxidative DNA damage caused by radiation and alkylating chemotherapy. It is approved for (1) prevention of cumulative cisplatin-induced renal toxicity and (2) reduction of moderate-to-severe xerostomia in post-operative head and neck cancer radiotherapy.

Critically, transient hypotension is amifostine’s most common clinically significant side effect, occurring in up to 60% of patients and requiring pre-hydration, supine positioning, and temporary treatment suspension protocols. This well-established pharmacological property — blood pressure reduction — creates a direct mechanistic contradiction against using amifostine to treat hypertension.

The TxGNN prediction most likely reflects knowledge graph topology rather than a genuine therapeutic opportunity. One literature study (PMID 40479584) links the Fanconi anemia complementation group L (FANCL) pathway to pulmonary arterial hypertension via endothelial DNA damage — and amifostine’s mechanism involves DNA damage prevention — creating an indirect graph node connection. However, this chain of inference is highly speculative and does not translate into a clinically actionable hypothesis. The 99.995% score reflects graph connectivity, not biological plausibility for this indication.

Clinical Trial Evidence

Currently no related clinical trials registered for amifostine in hypertensive disorder.

Literature Evidence

The 11 retrieved publications describe amifostine in oncology cytoprotection contexts; none directly investigate amifostine as a treatment for hypertension.

PMID	Year	Type	Journal	Key Findings
10755322	2000	RCT (cytoprotection)	Cancer Chemother Pharmacol	Compared amifostine vs. dexrazoxane for doxorubicin-induced cardiotoxicity using spontaneously hypertensive rats as an animal model — these are not hypertension treatment studies but cardiotoxicity protection studies
11335791	2001	Cohort Study	Anti-Cancer Drugs	Tolerability of amifostine in elderly vs. younger cancer patients (268 IV administrations); transient hypotension confirmed as the most common side effect
15560691	2004	Phase II Trial	J Med Assoc Thailand	Cisplatin-vinblastine + amifostine in advanced NSCLC; assessed whether amifostine reduces cisplatin toxicity without compromising antitumor efficacy
6286554	1982	Early Phase Trial	Int J Radiat Oncol Biol Phys	Phase I trials of WR-2721 with radiation therapy in 65 patients; established 740 mg/m² as well-tolerated single dose
6274534	1981	Phase I Trial	Cancer Clin Trials	Three Phase I trials of WR-2721 with radiation and alkylating agents (cyclophosphamide, cisplatin); maximum tolerated dose determination
19395196	2009	Cohort Study	Int J Radiat Oncol Biol Phys	Evaluated moderate wine consumption as a natural alternative to amifostine for radioprotection in breast cancer; amifostine noted for high cost and significant side effects
27855533	2016	Preclinical	Drug Delivery	Sustained-release microsphere formulation of amifostine to reduce injection frequency and blood-concentration-dependent side effects including hypotension
19915842	2010	Review	Eur J Nucl Med Mol Imaging	Review of kidney protection strategies during peptide receptor radionuclide therapy; amifostine mentioned as one nephroprotective option
40479584	2025	Mechanistic Study	Am J Respir Crit Care Med	FANCL pathway deficiency linked to pulmonary arterial hypertension via endothelial DNA damage — likely the knowledge graph source for TxGNN’s prediction; amifostine is not studied as a therapeutic agent in this paper
26130118	2015	Case Series/Review	Circulation	Mitomycin C-induced pulmonary veno-occlusive disease; chemotherapy identified as a risk factor for PH — peripherally related to hypertension by drug-induced pathway, not amifostine treatment

India Market Information

Amifostine is currently not marketed in India and has no registered product licenses on file.

Safety Considerations

Drug Interactions (134 total identified; key interactions listed below):

A particularly important pattern in the interaction data is that amifostine carries moderate-level interactions with multiple antihypertensive drug classes. Concurrent use would risk additive hypotension — further reinforcing that this drug is unsuitable for use in hypertensive patients rather than offering therapeutic benefit.

Interacting Drug	Level	Clinical Concern
Acebutolol (beta-blocker)	Moderate	Additive hypotension risk
Nifedipine (calcium channel blocker)	Moderate	Additive hypotension risk
Fosinopril (ACE inhibitor)	Moderate	Additive hypotension risk
Furosemide (loop diuretic)	Moderate	Additive hypotension/fluid depletion risk
Alfuzosin (alpha-blocker)	Moderate	Additive hypotension risk
Aliskiren (direct renin inhibitor)	Moderate	Additive hypotension risk
Hydrochlorothiazide (thiazide diuretic)	Moderate	Additive hypotension risk
Amiloride (potassium-sparing diuretic)	Moderate	Additive hypotension risk
Mannitol	Moderate	Additive hypotension/fluid balance alteration
Papaverine	Moderate	Additive vasodilatory / hypotensive effects
Foscarnet	Moderate	Renal and electrolyte monitoring required

Conclusion and Next Steps

Decision: Hold

Rationale: Amifostine’s established clinical pharmacology directly contradicts its use in hypertension: transient hypotension is its most common serious side effect, evidence is L5 (model prediction only) with zero clinical trials for this indication, and its interaction profile with standard antihypertensive drug classes creates compounding hypotensive risk rather than therapeutic synergy. The TxGNN high score likely reflects knowledge graph connectivity artifacts rather than a genuine repurposing signal.

To revisit this prediction, the following would first be required:

A clearly articulated mechanistic hypothesis that resolves the fundamental contradiction between amifostine’s blood-pressure-lowering side effect and its proposed antihypertensive use
Exploratory preclinical studies specifically examining amifostine in hypertension models (currently absent in the literature)
Confirmation that the TxGNN graph node connection via FANCL/PAH represents a true mechanistic pathway rather than a graph traversal artifact
Assessment of whether a structurally modified derivative of amifostine (without the hypotensive pharmacology) might retain any potential hypertension-relevant activity

Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.